Eli Lilly’s experimental drug retatrutide just pushed some patients past 28% of their body weight lost in a single late-stage trial, a number that puts it ahead of every obesity shot now on pharmacy shelves.
Quick Take
- Eli Lilly’s Phase 3 TRIUMPH-1 trial found patients on the highest dose lost an average of 70.3 pounds, or 28.3% of body weight, over 80 weeks.
- Nearly half of those patients, 45.3%, lost 30% or more of their starting weight, a level close to what bariatric surgery achieves.
- A second trial, TRIUMPH-2, showed strong weight loss plus blood sugar improvement in patients who also have type 2 diabetes.
- Lilly plans to ask the Food and Drug Administration (FDA) for approval in early 2027 after finishing its remaining Phase 3 studies.
What The Trial Actually Found
Eli Lilly ran TRIUMPH-1 as an 80-week, placebo-controlled study of adults with obesity. Patients on the 9 mg dose lost an average of 64.4 pounds, or 25.9% of their body weight. Those on the 12 mg dose lost 70.3 pounds, or 28.3%. Patients on placebo lost almost nothing by comparison, and the difference showed up on every major measure the company tracked.
The scale of that result stands out because most current obesity drugs top out well below 25% weight loss in real-world use. CNBC reported that roughly 45% of the 2,500 trial patients hit the 30% mark, a threshold once reserved for surgical weight-loss procedures like gastric bypass. Scientific American called the data a new high-water mark for the entire drug category.
A Second Trial Added Proof For Diabetes Patients
Lilly did not stop at one study. TRIUMPH-2 tested retatrutide in adults who have both obesity and type 2 diabetes, a group that often loses less weight on these drugs because of how diabetes affects metabolism. All three doses tested, 4 mg, 9 mg, and 12 mg, still delivered meaningful weight loss alongside better blood sugar control, meeting every goal the company had set for the trial.
Reuters reported that Lilly followed up with two more successful Phase 3 trials in July 2026, expanding the drug’s tested use to patients with serious complications like established heart disease. That steady drumbeat of positive results across different patient groups is what separates a real drug program from a one-time headline. Lilly is building a case file, not chasing a single splashy press release.
How This Fits The Bigger Weight-Loss Drug Race
Retatrutide works differently than earlier drugs like Ozempic or Wegovy. It targets three separate hormone receptors instead of one, which researchers believe is why the weight loss numbers keep climbing. Early Phase 2 data back in 2023 already showed up to 24.2% weight loss at 48 weeks, so the Phase 3 results extend a pattern rather than come out of nowhere.
That pattern matters for perspective. Obesity drug trials tend to produce big numbers in company press releases, and those numbers can shift once peer-reviewed papers and full safety tables come out. Lilly says detailed results will be published in medical journals and presented at scientific meetings this year, which is the normal next step before regulators weigh in.
Retatrutide Phase 3 Obesity Trial Results posted:
TRIUMPH-1, published today in NEJM:
2,339 adults. 80 weeks. Retatrutide hits GLP-1, GIP, and glucagon receptors.
Average weight loss at the top dose: 28.3%. About 70 pounds.
Nearly half of participants lost 30% or more-…
— Vita Bloom Labs (@vitabloomlabs) September 30, 2026
Side effects tracked in TRIUMPH-1 followed a familiar pattern for this drug class. Discontinuation due to adverse events rose with higher doses, from 4.1% at the low dose to 11.3% at the highest, compared with 4.9% on placebo. That is a real tradeoff patients and doctors will need to weigh, but it did not stop the trial from meeting its goals.
What Comes Next
Lilly is not asking the FDA to approve retatrutide yet. The company says it will submit its application in the first quarter of 2027, once remaining Phase 3 trials wrap up. Until then, retatrutide stays classified as an investigational drug, meaning it is not legally available by prescription for obesity treatment.
For the roughly 40% of American adults living with obesity, according to federal health data cited across years of research on this drug class, a treatment that rivals surgical outcomes without an operating room is a genuinely big deal. Real relief for millions of families dealing with weight-related health problems is worth taking seriously, and worth waiting for the full data to confirm.
Sources:
time.com, investor.lilly.com, theguardian.com, nbcnews.com
